Pulmonx Corporation's latest quarterly results showed a 4.0% increase in shares, with revenues meeting expectations and losses per share better than expected. Analysts predict a 23% revenue growth in 2025 despite anticipated losses. The consensus price target remains stable at US$13.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing